Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular diseaseEmpagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1Effect of empagliflozin on HHF was consistent in patients with and without established cardiovascular disease1Findings support data from the landmark EMPA-REG OUTCOME ® trial, in which empagliflozin reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease2
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news